Glucotrack (GCTK) Common Equity (2010 - 2025)

Glucotrack has disclosed Common Equity across 16 years of filings, most recently posting $2.8 million for Q4 2025.

• Quarterly Common Equity rose 121.75% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 121.75% YoY) and the FY2025 annual result came in at $2.8 million, up 121.75% from the prior year.
• Common Equity improved to $2.8 million in Q4 2025, from $2.8 million in the prior quarter.
• Over five years, Common Equity peaked at $8.1 million in Q1 2021 and troughed at -$13.0 million in Q4 2024.
• A 5-year average of $2.7 million and a median of $3.2 million in 2022 frame the typical range for Common Equity.
• Biggest YoY gain for Common Equity was 3309.09% in 2024; the steepest drop was 506.63% in 2024.
• Tracing GCTK's Common Equity over 5 years: stood at $5.2 million in 2021, then sank by 76.14% to $1.2 million in 2022, then surged by 159.92% to $3.2 million in 2023, then plunged by 506.63% to -$13.0 million in 2024, then jumped by 121.75% to $2.8 million in 2025.
• Business Quant data shows GCTK's Common Equity at $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $6.9 million in Q2 2025.